Philips Korea and HoneyNaps Sign Sleep and Cardiovascular Health MOU
Philips Korea, part of Royal Philips, and HoneyNaps signed a memorandum of understanding on August 19 to explore healthcare opportunities linking sleep disorders and cardiovascular health, the companies announced in a press release.
The partnership will focus on integrating sleep data with cardiovascular risk factors. The companies also plan to examine possible work in cardiology and other cardiovascular disease areas.
Philips Korea brings sleep and respiratory care products, healthcare provider networks, and commercial capabilities. HoneyNaps provides AI powered sleep medicine tools, including FDA authorized technology for sleep disorder diagnosis and analysis.
The companies said the collaboration may also include academic initiatives related to sleep and cardiovascular health.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Enterprise
More from: Life Sciences
Subscribe to Enterprise AI Brief
Weekly report on AI business applications, enterprise software releases, automation tools, and industry implementations.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read more